SCHEMBL1250842

SCHEMBL1250842

CC1(C)[C@@H]2CC[C@@H](CN)[C@H]1C2

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.49
RET P07949 1/20 0.49
CAMK1D Q8IU85 1/20 0.49
HDAC6 Q9UBN7 3/20 0.38
TBXA2R P21731 2/20 0.38
ALOX15 P16050 1/20 0.36
EPHX2 P34913 1/20 0.36
CXCR3 P49682 2/20 0.35
OPRM1 P35372 1/20 0.34
OPRK1 P41145 1/20 0.34
OPRL1 P41146 1/20 0.34
S1PR1 P21453 1/20 0.34
CNR2 P34972 1/20 0.33
CNR1 P21554 1/20 0.33
SCN9A Q15858 4/20 0.32
HSD11B1 P28845 1/20 0.32
SCN5A Q14524 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1155109 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL11971807 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL177081 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL1595257 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL11026742 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL14325015 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL177080 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL2811047 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL14393350 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R
SCHEMBL10209588 1.00 MAPK14 (0.49) MAPK14RETCAMK1DHDAC6TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119866217-A Agent for restoring metal steady state containing malonic acid or derivative thereof 牛津抗生素(制药)集团股份有限公司 2025-04-22 CN disclosed
CN-117561241-A Inhibitors of transglutaminase 策迪拉有限公司 2024-02-13 CN disclosed
WO-2023110138-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-22 WO disclosed
EP-4192813-A1 INHIBITORS OF TRANSGLUTAMINASES Zedira GmbH (DE) 2023-06-14 EP disclosed
WO-2023275336-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-01-05 WO disclosed
US-8937184-B2 1H-imidazole derivatives as cannabinoid CB2 receptor modulators ABBVIE B.V. (NL) 2015-01-20 US disclosed
EP-1741697-B1 CRYSTAL COMPRISING (2R)-2-PROPYLOCTANOIC ACID AND DIBENZYLAMINE ONO PHARMACEUTICAL CO (JP) 2012-12-19 EP disclosed
US-8273916-B2 Crystal comprising (2R)-2-propyloctanoic acid and amine ONO PHARMACEUTICAL CO., LTD. (JP) 2012-09-25 US disclosed
EP-1966146-B1 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS ABBOTT HEALTHCARE PRODUCTS BV (NL) 2011-03-02 EP disclosed
EP-1664005-B1 THIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS ABBOTT HEALTHCARE PRODUCTS BV (NL) 2011-02-09 EP disclosed
CN-101107233-A 1H-imidiazole derivatives as cannabinoid CB2 receptor modulators SOLVAY PHARM BV (NL) 2008-01-16 CN disclosed
EP-1874734-A1 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS Solvay Pharmaceuticals B.V. (NL) 2008-01-09 EP disclosed
WO-2007071662-A1 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS B.V. (NL) 2007-06-28 WO disclosed
US-20070142362-A1 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators SOLVAY PHARMACEUTICALS B.V. 2007-06-21 US disclosed
EP-1741697-A1 CRYSTAL COMPRISING (2R)-2-PROPYLOCTOIC ACID AND AMINE ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-10 EP disclosed
US-20060194779-A1 1H-imidazole derivatives as cannabinoid CB2 receptor modulators ABBVIE B.V. (NL) 2006-08-31 US disclosed
WO-2006087355-A1 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS B.V. (NL) 2006-08-24 WO disclosed
EP-1664005-A1 THIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS Solvay Pharmaceuticals B.V. (NL) 2006-06-07 EP disclosed
WO-2005028456-A1 THIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS B.V. (NL) 2005-03-31 WO disclosed
US-20050065189-A1 Thiazole derivatives as cannabinoid receptor modulators SOLVAY PHARMACEUTICALS B.V. 2005-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142362-A1 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators CNR1, CNR2, GPR55 MAPK14 1260/4885RET 731/4885CAMK1D 781/4885
US-20050065189-A1 Thiazole derivatives as cannabinoid receptor modulators CNR1, CNR2, NPY1R MAPK14 3723/4885RET 157/4885CAMK1D 939/4885
US-20060194779-A1 1H-imidazole derivatives as cannabinoid CB2 receptor modulators CNR1, CNR2, HRH4 MAPK14 2132/4885RET 353/4885CAMK1D 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.